Biopharma financings soared to $73.76 billion in the first seven months of 2024, marking a substantial 102% jump compared to the $36.47 billion accumulated in the same period in 2023. This amount places 2024 just behind the record-setting years of 2020 ($80.42 billion) and 2021 ($80.74 billion) in terms of funds raised through July. The $2.04 billion secured in July also is an increase from the $1.87 billion raised in June.

Airna Corp. Inc., of Cambridge, Mass., announced it has closed an oversubscribed $60 million financing round, bringing its total series A funding to $90 million.

Oxford Nanopore Technologies plc secured £80 million (US$102 million) in an oversubscribed equity raise, with £50 million coming from Novo Holdings.

LTZ Therapeutics Inc. has completed a series A financing of more than $20 million to advance the development of its myeloid engager pipeline to treat cancer and autoimmune diseases. The closing of this round brings LTZ’s total funding to about $50 million.

Protembis GmbH received €20 million (US$21.66 million) in financing from the European Investment Bank to develop its cerebral embolic protection system, Protembo. The intra-aortic filter device deflects embolic material away from arteries leading to the brain during left-sided heart procedures including transcatheter aortic valve replacement.